Long-lived, donor-reactive memory B cells (Bmems) can produce alloantibodies that mediate transplant injury. Autophagy, an intrinsic mechanism of cell organelle/component recycling, is required for Bmem survival in infectious and model antigen systems, but whether autophagy affects alloreactive Bmem is unknown. We studied mice with an inducible yellow fluorescent protein (YFP) reporter expressed under the activation-induced cytidine deaminase (AID) promoter active in B cells undergoing germinal center reactions. Up to 12 months after allogeneic sensitization, splenic YFP + B cells were predominantly IgD -IgM -IgG + and expressed CD73, CD80, and PD-L2, consistent with Bmems. Labeled cells contained significantly more cells with autophagosomes and more autophagosomes per cell than unlabeled, na€ ıve B cells. To test for a functional link, we quantified alloantibody formation in mice with B cells conditionally deficient in the requisite autophagy gene ATG7. These experiments revealed absent B cell ATG7 (1) prevented B cell autophagy, (2) inhibited secondary alloantibody responses without altering primary alloantibody formation, and (3) diminished frequencies of alloreactive Bmems. Pharmacological autophagy inhibition with 3-methyladenine had similar effects on wild-type mice. Together with new documentation of increased autophagosomes within human Bmems, our data indicate that targeting autophagy has potential for eliminating donorreactive Bmems in transplant recipients.
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Introduction
Antigen recognition via the B cell receptor in conjunction with cognate T cell interactions helps promote differentiation of IgD + IgM + na€ ıve B cells into antibody secreting B cells, plasma cells (PCs), and class-switched (i.e. IgG + ) memory B cells (Bmems) (1) . Reactivation of long-lived IgD -IgG + murine Bmems permits them to rapidly develop into antibody-secreting cells (ASCs). Resultant anamnestic antibody responses develop with accelerated kinetics and higher affinity than primary responses and are considered essential for protection against pathogen reinfection (1) .
Analogous primary and anamnestic responses induced to alloantigen represent significant barriers to transplant survival (2, 3) . Current concepts are that donor-specific antibodies (DSA) generated from host exposure to alloantigen via blood transfusions, pregnancy, heterologous immunity, and/or prior transplantations are responsible for antibody-mediated allograft injury that results in graft failure (2) . While long-lived PCs can produce DSAs in sensitized mice and humans, emerging evidence indicates that posttransplantation DSAs in sensitized individuals commonly derive from reactivation of Bmems (3). Current desensitization regimens are largely focused on neutralizing or removing circulating serum antibody (e.g. antithymocyte globulin and plasmapheresis) or eliminating PCs (e.g. bortezomib). Recognition that donor-reactive Bmems, even in the absence of detectable DSAs, are strongly associated with antibody-mediated kidney allograft injury (3) supports the need to better understand the mechanisms of Bmem cell function and survival to guide improved therapeutic interventions.
Autophagy is a cell intrinsic process involving sequestration of organelles or cytoplasmic constituents within de novo organelles called autophagosomes and degradation after fusion with a lysosome. Autophagy is a powerful homeostatic mechanism and is important for removing damaged organelles or repurposing unused cytoplasmic material. The autophagy pathway involves two distinct ubiquitin ligase-like pathways that require the E1-ligaselike activity of the protein autophagy related gene 7 (ATG7) (4) . The first of these pathways facilitates conjugation of ATG5 to ATG12, a process requiring initial activation of ATG12 via ATG7-mediated creation of a thioester bond (5) . ATG7 is also necessary for the conjugation of a phospholipid, phosphatidylethanolamine, to microtubule-associated protein light chain 3 (LC3) that, along with conjugation of ATG5 to ATG12, permits expansion of the autophagosome (6) . The phosphatidylethanolamineconjugated form of LC3, termed LC3-II, remains part of the completed autophagosome. This phenomenon is unique to LC3 and is the basis for most experimental autophagy measurement assays (7).
Canonically, autophagy is an adaptation to insufficient nutrient availability (8) . Increasing evidence suggests that autophagy induction occurs via multiple stimuli including pattern recognition receptors, cytokines, oxidative stress, and endoplasmic reticulum stress (9) (10) (11) (12) . Autophagy is also necessary for the maintenance of neurons and other long-lived cells (13) . Emerging evidence suggests that B cell autophagy is necessary for antipathogen Bmem survival but the effects of autophagy on Bmem-dependent alloantibody production after transplantation remain unknown (14) .
Here, we show that B cell intrinsic autophagy is required for allospecific Bmem cell function in mice. Our new data indicate that pharmacological autophagy inhibition can prevent anamnestic DSA responses to alloantigen. Together with our new observation that human Bmems contain autophagomes, our findings support the need to develop and test analogous desensitization strategies in alloantigen-exposed human transplant candidates.
Materials and Methods

Animals
Wild-type (WT) C57BL/6 (B6), BALB/cJ (BALB/c), and B6 CD19-Cre transgenic mice were purchased from Jackson Laboratories (Bar Harbor, ME). Activation-induced cytidine deaminase (AID)-Cre-ERT2-Rosa26-enhanced yellow fluorescent protein (eYFP) mice were provided by N. Papavasiliou (Rockefeller University; New York, NY) and have been previously described (15) . ATG7fl/fl mice (B6 background) (16) were crossed to CD19-Cre mice to produce CD19Cre 9 ATG7fl/fl. Green fluorescent protein (GFP)-LC3 reporter mice were provided by Zhenyue Yue (Icahn School of Medicine at Mount Sinai) (17) . All animals were housed in the Center for Comparative Medicine and Surgery at the Icahn School of Medicine at Mount Sinai under Institutional Animal Care and Use Committee approval.
In vivo animal studies
Sensitization was performed with two intraperitoneal. injections of 15 9 10 6 donor spleen cells into recipient allogeneic recipients administered 2 weeks apart. Vascularized heterotopic heart transplantations were performed as previously described (18) 
Western blot
Western blotting was conducted as previously described (19) using anti-LC3 (MBL, Woburn, MA), anti-p62 (MBL), anti-GAPDH (Sigma), horseradish peroxidase-conjugated donkey anti-rabbit (Jackson Immunoresearch, West Grove, PA), and goat anti-guinea pig (Invitrogen, Carlsbad, CA). Band intensity quantification was performed by using Image Studio (Licor, Lincoln, NE).
Flow cytometry
Eight-parameter flow cytometric analysis was performed as previously described (20) on an FACSCanto II flow cytometer using DiVA software package (BD, Franklin Lakes, NJ). Data were analyzed using FlowJo software (Tree Star, Ashland, OR). Murine cell surface staining was performed by using fluorescently labeled monoclonal antibodies reactive to B220, IgD, IgM, and IgG (all from eBioscience, San Diego, CA) and CD73, CD80, and PD-L2 (all from BD Biosciences, San Jose, CA). Surface staining in human cells was performed with fluorescently labeled antibodies reactive to CD19, IgD, and CD27 (BD Biosciences). For tetramer staining, biotinylated monomers of H-2K d loaded with a peptide whose sequence (SYIPSAEKI) possesses a defined specificity (21) were obtained from the National Institutes of Health (NIH) Tetramer Core Facility (Atlanta, GA). Tetramerization was performed per NIH protocol (http:// tetramer.yerkes.emory.edu/support/protocols#10) with streptavidin conjugated phycoerythrin and allophycocyanin (Thermo Fisher Scientific, Carlsbad, CA). One microliter of each tetramer was added to 5 million cells for each condition tested.
B cell isolation
Primary murine B cells were obtained from freshly isolated splenic singlecell suspensions by using EasySep TM Mouse B Cell Isolation Kit (STEM-CELL Technologies, Cambridge, MA) per the manufacturer's instructions. Purified YFP + and YFP -AID-CreERT2-eYFP B cells were enriched as described above and then sorted to >90% purity on a SONY SH800Z sorter (San Jose, CA) before enzyme-linked immunosorbent spot (ELISPOT) analysis. For human B cell experiments, peripheral blood mononuclear cells (PBMCs) were isolated as previously described (20) from leukopacs of anonymous donors purchased from the New York Blood Bank. B cells were then isolated from total PBMCs by using the EasySep TM Human B Cell Isolation Kit (STEMCELL Technologies).
Imaging flow analysis
Quantification of autophagosomes was accomplished by using imaging flow cytometry as determined by LC3 puncta. Mouse and human B cells were fixed with paraformaldehyde and then stained with an anti-LC3 DyLight 650 (Thermo Fisher Scientific, Carlsbad, CA). Cell images were acquired on an ImageStream flow cytometer (Amnis, Seattle, WA) and analyzed with the IDEAS analysis software (Amnis). Single-color controls were used for creation of a compensation matrix that was applied to all files to correct for spectral crosstalk. Debris and dead cells were identified by high pixel intensity correlation (Bright Detail Similarity score) across all channels and were excluded from the analysis.
To quantify LC3 spots per B cell, masks were created to identify DyLight 650 or GFP intensity peaks p-fold greater than the background with a diameter of r number of pixels. The optimal p and r were determined independently for each experiment. Controls for the efficacy of the algorithm were performed by using unstained samples (22) . The number of individual masks in each cell was enumerated, and histograms of the distribution of spots per cell were obtained for each sample.
Donor-specific alloantibody
To quantify class I IgG DSAs, serial dilutions of recipient serum were incubated with 250 000 freshly isolated donor thymocytes. Cells were washed and then incubated with FITC-conjugated anti-mouse IgG antibody (eBioscience). Detection of antibody binding was accomplished by flow cytometry on an FACSCanto II flow cytometer (at least 10 000 events per sample). Negative controls to define background staining included use of serum from na€ ıve animals and thymocytes mixed with secondary antibody in the absence of serum.
B cell ELISPOT
ELISPOTs were performed by using MABTECH B cell ELISPOT kits according to the manufacturer's instructions. Briefly, 96-well PVDF plates were coated with IgG capture antibody overnight. Isolated spleen cells in RPMI 5% FBS (Thermo Fisher Scientific) were plated and incubated overnight. The following day, plates were washed and incubated with biotinylated detection agents (either anti-IgG or monomers of H-2K d ).
Biotinylated H-2K d monomers able to detect a subset of alloreactive ASCs (peptide sequence SYIPSAEKI) were provided by the NIH Tetramer Core Facility (21) .
Statistics
For all experiments, results are expressed as meanAESEM. Determination of significance was done by using the Student t-test (GraphPad Prism; GraphPad, La Jolla, CA) with a value of p < 0.05 considered significant. The number of punctate-containing B cells in sets of 3MA or controltreated GFP-LC3 mice were compared by using Fisher's Exact Test with p < 0.05 considered significant.
Results
Identification of alloantigen-induced Bmems by fate mapping
To identify allospecific Bmems in vivo, we used a mouse model with an inducible YFP reporter driven by the promoter for AID, a protein restricted to B cells and required for germinal cell (GC) formation and affinity maturation (15) . Tamoxifen treatment of AID-expressing AIDCreERT2-eYFP mice produces cleavage of loxP sites surrounding a "stop" codon downstream of the Rosa26 promoter enabling irreversible YFP production and permanently identifying B cells that have undergone GC reactions related to affinity maturation and memory cell formation (15) .
We transplanted BALB/c hearts into B6 AID-CreERT2-eYFP mice and treated the recipients with tamoxifen from days 7 through 14 ( Figure 1A ) to irreversibly label B cells engaged in GC reactions during that time period. Four months later, analyses showed that YFP + splenic B cells were predominantly IgD -IgM -IgG + consistent with a class-switched memory phenotype ( Figure 1B-E) . In contrast, the YFP -population was overwhelmingly IgD + IgM + IgG -( Figure 1B-E) . In comparison to YFP -na€ ıve B cells, YFP + B cells from mice sensitized with BALB/c splenocytes 12 months earlier expressed higher levels of CD73 and contained a higher frequency of CD80/PD-L2 double-positive cells (Figure 1F-I) . consistent with previous findings by others indicative of a memory phenotype (23, 24) . When we analyzed splenic B cells from these mice for binding to donor H-2K d by using dual tetramer staining and flow cytometry (21) (Figure 1 J,K) , we observed significantly higher frequencies of K d -reactive B cells within the YFP + population. Control experiments showed that labeling na€ ıve mice yielded a YFP + population capable of producing IgG but not DSAs ( Figure S1 ). Together, the data support the conclusion that that YFP + cells generated during allosensitization in this system are predominantly IgG + Bmems that are enriched for reactivity to donor MHC.
Increased autophagy in Bmems
During autophagy induction, LC3 molecules coalesce onto nascent autophagosome membranes, appearing as fluorescent puncta that can be quantified through imaging flow cytometry. We analyzed and compared LC3 expression patterns by imaging flow cytometry in the YFP + Bmems and YFP -B cells from recipients of allogeneic BALB/c hearts 4 months after transplantation (Figure 2A) . These studies revealed significantly higher frequencies of punctate LC3 + cells and more punctate regions per cell in the YFP + cells (Figure 2B,C) . In conjunction with our documentation that the YFP + population is enriched for donor-reactive B cells (Figure 1 ), our findings confirm increased autophagy in Bmems and provide evidence for ongoing autophagy within alloreactive Bmems.
Secondary alloantibody responses require B cell autophagy
In an effort to link B cell autophagy to Bmem function, we used CD19Cre + 9 ATG7fl/fl conditional knockout mice, in which deletion of ATG7 is restricted to B cells (14) . Absence of ATG7 prevents activation of LC3-I to LC3-II, thereby impairing autophagosome formation/ function (6) . In confirmation of the expected phenotype, B cells from CD19Cre + 9 ATG7fl/fl mice do not contain LC3-II and, as further evidence of impaired autophagic degradation, have increased abundance of autophagy substrate p62 compared with controls ( Figure 3A) . Control experiments performed with B cell-depleted spleen cells from CD19Cre + 9 ATG7fl/fl mice and ATG7fl/fl controls confirmed that the autophagy defect is restricted to B cells ( Figure 3B,C) .
To determine whether B cell autophagy affects secondary antibody recall responses, we quantified and compared the kinetics of serum DSA (anti-donor class I MHC) in CD19Cre + 9 ATG7fl/fl mice and control littermates after primary and secondary stimulations with alloantigens. Two weeks after sensitization with allogeneic spleen cell injections into na€ ıve CD19Cre + 9 ATG7fl/fl and control ATG7fl/fl mice, we observed identical titers of serum IgG DSAs ( Figure 4A ). Eight weeks after sensitization, serum IgG DSA titers had fallen equivalently in both groups ( Figure 4B ). We next challenged both groups of sensitized animals, 8 weeks after initial sensitization, with BALB/c spleen cells and measured serum IgG DSAs beginning 5 days later, a time point too early for initiation of a de novo class-switched antibody response. Whereas IgG DSA titers increased rapidly and significantly in the control ATG7 fl/fl animals consistent with known kinetics of a secondary response (1), we observed significantly impaired induction of IgG DSAs in CD19Cre + 9 ATG7fl/fl mice ( Figure 4C,D) .
In an effort to test the effects of B cell autophagy in a system that mimics clinical transplantation into sensitized recipients, we next injected CD19Cre + 9 ATG7fl/fl mice and control ATG7fl/fl littermates with BALB/c spleen cells and 5 months later transplanted them with BALB/c heart allografts under the cover of anti-CD40L mAb MR1 (the latter to limit anti-donor T cell responses and retard cellular rejection, Figure 4E ). As in the previous experiments ( Figure 4A-D) , the kinetics and titers of the primary DSA responses were similar between the groups at all time points, including 5 months after the immunization (immediately before transplantation), where only low titers of IgG DSA were detected ( Figure 4F ). Seven days after heart transplantation, sera of CD19Cre + 9 ATG7fl/fl mice contained significantly lower titers of IgG DSA than control mice (Figure 4G ), which represented modest changes from pretransplantation levels and were significantly less than the changes in control mice ( Figure 4H ).
We next isolated splenic B cells from the same animals on day 7 posttransplantation to test them for their ability to produce donor-reactive (H-2K d ) IgG with the use of ELISPOT. These assays showed significantly lower frequencies of allospecific ASCs in CD19Cre + 9 ATG7fl/fl mice ( Figure 4I ,J).
Pharmacological inhibition of autophagy impairs antibody recall response
In an attempt to translate these findings to a clinically relevant treatment strategy, we tested the effects of 3MA, a chemical inhibitor of autophagy that blocks the proximal class III phosphoinositide 3-kinase complex, on induction of secondary alloantibody responses in vivo (25) . To verify that 3MA impairs autophagy in vivo, we injected a GFP-LC3 mouse, in which autophagosome formation is indicated by the presence of punctate green fluorescence, with 3MA. When B cells from these mice were compared with the cells from control mice, we found significantly fewer cells containing punctate fluorescence in treated mice compared with controls (p < 0.01 by Fisher's Exact Test, repeated three times, data not shown). We then sensitized WT B6 mice with BALB/c spleen cells as described, and 5 weeks later (at a time when Bmems have been formed), we treated recipients with 3MA or vehicle every 5 days for 3 weeks. Serum lgG DSA titers did not differ between the groups after sensitization or at the end of the treatment period (although titers were lower at 8 weeks than at 5 weeks in both groups, Figure 5A ). We then challenged the animals with injections of BALB/c spleen cells and analyzed serum DSAs 5 days later. These assays showed significantly lower changes of IgG DSAs in the 3MA-treated mice ( Figure 5B ). Quantification by ELISPOT also showed fewer splenic allospecific ASCs in 3MA-treated mice compared with controls (data not shown). We repeated this experiment in mice sensitized similarly but treated with 3MA for 3 weeks, beginning 10 months after sensitization. Prechallenge titers did not differ between treated and control groups ( Figure 5C ), but increases in post-challenge antibody production were again impaired in the treated group ( Figure 5D ). 
Discussion
Our findings add to a growing body of work demonstrating the particular importance of autophagy in immune cell memory (14, 27, 28) in several ways. Our work is the first to address the effect of autophagy on immunological B cell memory in transplantation. Use of the AID-CreERT2-eYFP mice permitted us to identify YFP + B cells that underwent GC reactions following the initial alloimmune stimulus and that persisted up to 1 year later. This fatemapping approach defined and identified Bmems (class switched and persisting for months after GC reaction), circumventing less reliable identification based on cell surface marker phenotyping. We confirmed that YFP + B cells were enriched for class-switched IgG + anti-H-2K d allospecific cells (Figure 1 ).
We next leveraged this system to extend work by others (14, 29) , using a distinct methodology, to demonstrate that autophagy is preferentially more active within Bmems. Our imaging flow analysis of LC3-stained B cells corroborates the seminal findings first observed in infectious and model antigen systems (14, 29) . The scarcity of allospecific Bmems and difficulty in identifying them compared with those resulting from model antigen sensitization (i.e. NP-KLH) prevented us from definitively identifying increased autophagy within allospecific Bmems. However, when taken in the context of published data on autophagy-dependent Bmem responses to other stimuli and given the demonstrated enrichment of allospecific cells in the YFP + subset (Figure 1 ), we provide compelling data supporting that autophagy is increased in allospecific Bmems.
We also provide new evidence that B cell intrinsic autophagy is required for secondary alloantibody responses (Figure 4) . Recall alloantibody responses initiated by injection of allogeneic spleen cells or by a heart allograft and quantified before de novo GC reactions (30) revealed strikingly fewer alloreactive IgG ASCs and impaired production of IgG DSAs in CD19Cre + 9 ATG7fl/fl mice, indicating that B cell intrinsic autophagy is required for the function and/or survival of alloreactive Bmems. Oxidative stress from dysfunctional mitochondria accumulates with age, is exacerbated in the absence of autophagy (31) , and could explain decreased survival in autophagy-deficient Bmems. In support of this, previous work has shown that treatment of autophagy-deficient pathogenspecific Bmems with free radical scavengers (e.g. N-acetylcysteine) partially rescues survival (14) . While our data cannot differentiate Bmem function versus survival, we speculate, based on the work of Chen et al, that B cell intrinsic autophagy primarily mediates survival of long-lived Bmems. In contrast to its effect on secondary responses, and consistent with work performed in antiviral immunity using the same murine model (29) , our data show that absent B cell autophagy does not affect primary alloantibody responses. Our results differ somewhat from published work that showed decreased primary antibody responses in CD19Cre 9 ATG5fl/fl mice (32) . The published work was performed in a different system (ATG5-deficient mice). We speculate that the findings in the ATG5-deficient mice differ from our results (and those of Chen et al) because of autophagyindependent ATG5 effects that have been documented in other systems (33) . Finally, the short lifespan of na€ ıve B cells (days to weeks) (34) may also explain why autophagy is dispensable in this group. Conversely Bmems, detected decades after their generation, have an indefinite lifespan with increased dependence on autophagy for survival (35) .
An additional new observation of clinical relevance is that pharmacological inhibition of autophagy using 3MA mitigated secondary alloantibody formation even when treatment was initiated 10 months after the sensitizing stimulus ( Figure 5C ,D). 3MA does have documented autophagy-independent effects (e.g. its use in immune cells is associated with altered innate immunity and intracellular signal transduction pathways) (36) . Several other candidate autophagy inhibitors exist but, similar to 3MA, indirectly inhibit autophagy (37) . Ideal pharmacological agents would affect the autophagy pathway more specifically.
Last, we show for the first time that autophagy is increased in human Bmems. A sensitized kidney transplant recipient can harbor antidonor Bmems that exist in the absence of DSAs but are capable of differentiating into alloreactive ASCs (3). Our observation in human Bmems together with the murine data support the need to test whether inhibiting B cell autophagy could selectively inhibit secondary alloantibody responses in sensitized individuals.
In conclusion, our work demonstrates an essential role for autophagy in the function and/or survival of Bmems in the context of transplantation. Together, the findings delineate B cell autophagy as a previously unrecognized therapeutic target for preventing DSA production and associated allograft injury in sensitized transplant candidates.
